Sarepta surges following results for Eteplirsen therapy

Sarepta (SRPT) shares jump 19% after the company said late yesterday that its Eteplirsen treatment for Duchenne Muscular Dystrophy performed well in a Phase IIb study, with the therapy enabling "continued stability on a walking test through 120 weeks."

After releasing the news, Sarepta gave a presentation at the JPMorgan Healthcare Conference, which you can see here. You can hear the Webcast here.

From other sites
Comments (1)
  • pat walsh
    , contributor
    Comments (347) | Send Message
    One word for SRPT shorts.ICPT.
    17 Jan 2014, 12:08 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs